Results 131 to 140 of about 567,668 (313)

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease. [PDF]

Curr Neuropharmacol, 2023
Jing XZ, Yang HJ, Taximaimaiti R, Wang XP.   +3 more
europepmc   +1 more source

Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.

European Journal of Endocrinology, 2016
Y. Greenman, Odelia Cooper, I. Yaish, E. Robenshtok, Nadav Sagiv, T. Jonas-Kimchi, Xiaopu Yuan, Arkadiusz Gertych, Ilan Shimon, Zvi Ram, S. Melmed, N. Stern   +11 more
semanticscholar   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. [PDF]

Front Endocrinol (Lausanne), 2021
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.   +6 more
europepmc   +1 more source

Ectopic dopamine agonist-resistant macroprolactinoma to the clivus masquerading as a chordoma – A case report [PDF]

I. Bayar, Atef Ben Nsir, Sana Abid, B. Ben Amor, H. Marmouch, Asma Ben Mabrouk, Kais Maamri, Jamel Saad, Mehdi Darmoul, I. Khochtali   +9 more
openalex   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine [PDF]

, 2021
Marianne Clausen, Rasmus Rørth, Christian Torp‐Pedersen, Lucas Malta Westergaard, Peter Weeke, Gunnar Gislason, Lars Køber, Emil Loldrup Fosbøl, Søren Lund Kristensen   +8 more
openalex   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas. [PDF]

Acta Endocrinol (Buchar), 2021
Capatina C, Poiana C.
europepmc   +1 more source